Figure 3.

MLDL1278a modulates inflammatory signaling and inhibits various inflammation stimuli. (A) MCP-1 concentration from monocytes treated with control antibody and MLDL1278a in combination with a variety of inflammatory stimuli. The corresponding receptor for each of these stimuli is illustrated at the bottom. MCP-1 level from LPS stimulated cells with no antibody treatment was set as 100%. (B) Immunoblot analysis of phosphorylation or total amount of the indicated protein in the presence of control antibody, MLDL1278a or MLDL1278a DANA mutant (M-DANA), in the absence or presence of 0.3 ng/ml LPS. (C) Quantification of the western blotting. The intensity of the phosphor-protein bands is normalized against the corresponding total protein bands, and total IκBα is normalized to actin. Data shown are average+SEM from 3 independent experiments. (D) Schematic representation of the proposed mechanism for anti-oxLDL immune complex and FcγRs mediated anti-inflammatory effect.